Here's why the Rhythm (ASX:RHY) share price is soaring 8% today

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22. Here's what the company announced to the ASX.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22.

During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%.

Rhythm moves ahead with strategic plans

Investors appear to be pleased with the company's progress to commercialise its cancer detection technology, ColoSTAT, driving Rhythm shares higher.

In its announcement, Rhythm highlighted a number of activities that it is moving forward to launch ColoSTAT into global markets.

The first of its listed strategic initiatives is to accelerate United States market entry for ColoSTAT. The company has incorporated a wholly-owned entity to cement its foothold in the country to carry operations out smoothly. The initial pathway stages to obtain market approval from the United States Food and Drug Administration (FDA) has already commenced.

In addition, Rhythm has expanded its platform by setting up an Australian entity to hold its technology within. The company validated initial data that its lead biomarker has a global market opportunity for cancer diagnostics.

Regulatory entry in both Europe (CE Mark) and Australia is advancing ahead of completion in its ColoSTAT Study 7. CE Mark filing is slated for late 2021, and the Australian Therapeutic Goods Administration (TGA) has begun the regulatory approval process.

Lastly, the company is looking at further market entry strategies in Europe, Australia, New Zealand, China, and broader Asia. Further updates in regards to this are expected to be released to the ASX in the coming months.

Notably, the company is targeting its first revenue for late 2022.

Comments from the CEO

Rhythm CEO, Mr. Glenn Gilbert commented:

Following the exceptional ColoSTAT performance results from Study 6 and the LRF algorithm enhancement work, this has given the company confidence to now accelerate the execution of our commercial strategy, focusing on our path to market activities.

ColoSTAT will transform the global mass-market cancer diagnostic market, with exciting and positive impacts at a social and economic level.

About the Rhythm share price

The Rhythm share price has been one of the best performers over the last 12 months, rising more than 1,000%. The company's shares were trading at 6.3 cents in June before accelerating later that year.

It's worth noting that the Rhythm share price is trading just below its all-time high of $1.675, reached in March.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »